Skip to Content
Merck

Cysteine is a limiting factor for glioma proliferation and survival.

Molecular oncology (2021-12-03)
Victor Ruiz-Rodado, Tyrone Dowdy, Adrian Lita, Tamalee Kramp, Meili Zhang, Jinkyu Jung, Ana Dios-Esponera, Lumin Zhang, Christel C Herold-Mende, Kevin Camphausen, Mark R Gilbert, Mioara Larion
ABSTRACT

Nutritional intervention is becoming more prevalent as adjuvant therapy for many cancers in view of the tumor dependence on external sources for some nutrients. However, little is known about the mechanisms that make cancer cells require certain nutrients from the microenvironment. Herein, we report the dependence of glioma cells on exogenous cysteine/cystine, despite this amino acid being nonessential. Using several 13 C-tracers and analysis of cystathionine synthase and cystathioninase levels, we revealed that glioma cells were not able to support glutathione synthesis through the transsulfuration pathway, which allows methionine to be converted to cysteine in cysteine/cystine-deprived conditions. Therefore, we explored the nutritional deprivation in a mouse model of glioma. Animals subjected to a cysteine/cystine-free diet survived longer, although this increase did not attain statistical significance, with concomitant reductions in plasma glutathione and cysteine levels. At the end point, however, tumors displayed the ability to synthesize glutathione, even though higher levels of oxidative stress were detected. We observed a compensation from the nutritional intervention revealed as the recovery of cysteine-related metabolite levels in plasma. Our study highlights a time window where cysteine deprivation can be exploited for additional therapeutic strategies.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Isocitrate Dehydrogenase 1 (IDH1)-R132H Antibody, clone HMab-1, clone HMab-1, from mouse